SpaceX IPO is the biggest IPO in stock market history. Join the conversation.Click here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTristel Regulatory News (TSTL)

Share Price Information for Tristel (TSTL)

Share Price is delayed by 15 minutes
Get Live Data
392.00    2.00 (0.51%)
Bid:
385.00
Ask:
399.00
Spread: 14.00 (3.636%)
Market Cap: £188.15m
TSTL Live PriceLast checked at - London Stock Exchange

Intraday Tristel Share Chart

CFO succession planning

15 May 2025 07:00

RNS Number : 7165I
Tristel PLC
15 May 2025
 

TRISTEL plc

("Tristel" or the "Company" or the "Group")

 

CFO succession planning

 

Tristel plc (AIM: TSTL), the manufacturer of infection prevention products, announces that Liz Dixon, Chief Financial Officer ("CFO"), has confirmed to the Board her intention to retire from the business on 30 June 2025.

 

A process to appoint a new CFO is well underway and the Board has been pleased with the quality of candidates showing an interest in the position. A further announcement will be made in due course.

 

Bruno Holthof, Chair of the Tristel Board, commented: "On behalf of the Company I would like to offer my thanks to Liz for her contribution to the business over the years. Liz has been involved with Tristel since July 2007 when she joined as Group Chief Accountant, before becoming Finance Director of our main trading subsidiary in August 2009, and ultimately joining the Board in June 2010. She played a critical role in securing market access to North America and has positioned Tristel very well for continued profitable growth."

 

Matt Sassone, Chief Executive Officer of Tristel, commented: "Since Liz joined Tristel, the company has grown considerably, and Liz has played a pivotal role in that success. In addition to supporting the operational side of the business, she has been instrumental in driving our commercial performance and built a robust, capable finance team-ensuring we are well-positioned for the continued expansion we anticipate in the years ahead.

 

"It has been a pleasure to work with Liz over the last nine months, and I am grateful that due to her stewardship I have joined a business with a very strong financial position, and well-funded to deliver further organic commercial growth."

 

Liz Dixon, Chief Financial Officer of Tristel, commented: "Whilst I am very sad to be leaving Tristel after nearly 18 years, I do so happy in the knowledge that the business is well placed both financially and commercially for its next stage of growth under the leadership of Matt and the senior team.

 

"It has been a great pleasure to have been part of an amazing UK success story, and to see Tristel establish a leading position in the global infection prevention world. I wish the incredible Tristel team the very best and am confident that they will continue to deliver to our shareholders."

 

The information communicated in this announcement is inside information for the purposes of Article 7 of Regulation 596/2014.

 

 

For further information please contact:

 

Tristel plc

Via Walbrook PR

Matt Sassone, Chief Executive Officer

www.investors.tristel.com

Liz Dixon, Chief Financial Officer

Walbrook PR Ltd

Tel: 020 7933 8780 or tristel@walbrookpr.com

Paul McManus / Lianne Applegarth / Alice Woodings 

Mob: 07980 541 893/ 07584 391 303/ 07407 804 654

Cavendish Capital Markets Ltd

Tel: 020 7220 0500

Geoff Nash / Trisyia Jamaludin (Corporate Finance)

Sunila de Silva (Corporate Broking) / Louise Talbot (Sales)

 

About Tristel plc

Tristel plc is a global infection prevention company focussed on the manufacture and supply of products using its unique proprietary chlorine dioxide (ClO2) chemistry. The Company is a market leader in manual decontamination of medical devices, supplying hospitals under the Tristel brand, and under the Cache brand provides products for sporicidal surface disinfection, a more sustainable alternative to commonly used pre-wetted plastic wipes.

 

Tristel's head office and manufacturing facility is located in Snailwell, near Cambridge, and operates globally employing approximately 270 people across 16 subsidiaries selling into 40+ countries. The Company targets annual revenue growth of between 10% and 15% and an EBITDA margin of at least 25% and the business is profitable, with no debt and has a progressive dividend policy.

 

The Company has been listed on the London Stock Exchange's AIM market since 2005 (AIM: TSTL).

 

For more information about Tristel's product range please visit: https://tristel.com

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
BOAFLFFREIISLIE
Date   Source Headline
10th Jun 20267:00 amRNSExercise of Share Options & Total Voting Rights
13th May 202610:10 amRNSExercise of Share Options and Total Voting Rights
5th May 20267:00 amRNSExercise of Share Options and Total Voting Rights
20th Apr 20262:28 pmRNSHolding(s) in Company
20th Apr 20268:20 amRNSHolding(s) in Company
23rd Mar 20267:00 amRNSDirector/PDMR Shareholding
18th Mar 20267:00 amRNS-RConference attendance at ShareSoc Leeds
17th Mar 20265:13 pmRNSHolding(s) in Company
3rd Mar 20264:04 pmRNSPCA Dealing
2nd Mar 20267:00 amRNSHalf-year Financial Report
12th Feb 20267:00 amRNSExercise of Share Options and Total Voting Rights
6th Feb 202611:56 amRNSExercise of Share Options and Total Voting Rights
6th Feb 20267:00 amRNSNotice of Results
22nd Jan 20267:00 amRNSPositive H1 Trading Update & Directorate Change
8th Jan 20263:10 pmRNSExercise of Share Options and Total Voting Rights
12th Dec 202510:37 amRNSDirector/PDMR Shareholding
12th Dec 20259:19 amRNSExercise of Share Options and Total Voting Rights
11th Dec 202511:54 amRNSResult of AGM
11th Dec 20257:00 amRNSAGM Statement
24th Nov 202512:28 pmRNSDirector Option Grant
24th Nov 20257:00 amRNSUpdated US guidelines for high level disinfection
18th Nov 20257:00 amRNSNotice of AGM & Posting of Annual Report &Accounts
12th Nov 202511:33 amRNSHolding(s) in Company
31st Oct 20254:11 pmRNSHolding(s) in Company
31st Oct 20252:12 pmRNSHolding(s) in Company
22nd Oct 20254:56 pmRNSHolding(s) in Company
16th Oct 20254:00 pmRNSExercise of Share Options and Total Voting Rights
13th Oct 202512:00 pmRNSExercise of Share Options and Total Voting Rights
13th Oct 20257:00 amRNSFinal Results
9th Oct 202510:06 amRNSExercise of Share Options and Total Voting Rights
25th Sep 20257:00 amRNSVISICLEAN Product Launch
16th Sep 20257:00 amRNSNotice of Preliminary Results
11th Sep 20257:00 amRNSExercise of Share Options and Total Voting Rights
1st Sep 20257:00 amRNSConfirmation of CFO Appointment
21st Aug 20253:56 pmRNSHolding(s) in Company
18th Aug 202512:15 pmRNSExercise of Share Options and Total Voting Rights
6th Aug 20254:05 pmRNS-RCapital Markets Day video update
29th Jul 20257:00 amRNSTrading update
24th Jul 20257:00 amRNSConfirmation of Investor presentations
17th Jul 20257:00 amRNSAppointment of Chief Financial Officer
4th Jul 20251:02 pmRNSHolding(s) in Company
26th Jun 20257:00 amRNS-RAPIC25 Annual Conference attendance
2nd Jun 20257:00 amRNSInvestor Presentations & Notice of Trading Update
30th May 20257:00 amRNSHolding(s) in Company
28th May 20257:00 amRNS-RConference attendance at Mello2025 Investor event
16th May 20257:00 amRNSExercise of Share Options and Total Voting Rights
15th May 20257:00 amRNSCFO succession planning
12th May 20257:00 amRNSFDA clearance for Tristel OPH
10th Apr 20257:00 amRNSAdditional info. submitted to FDA for Tristel OPH
9th Apr 20257:00 amRNSPublication of Poster by Mayo Clinic & US update

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.